Evidence map›Paper›PMID 42528594›Full record

ArticlebioRxiv : the preprint server for biology2026

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer.

Ryan J Rebernick, Liat Hammer, Mahnoor Gondal, Abhijit Parolia, Yi-Mi Wu, Noshad Hosseini, Matthew Schipper, Anbarasu Kumaraswamy, Matthew McFarlane, Xuhong Cao and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Ryan J RebernickDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID 0000-0002-5532-581X
Liat HammerDepartment of Radiation Oncology, Sheba Medical Center, Ramat Gan, Israel; School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Mahnoor GondalDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID 0000-0002-9419-6758
Abhijit ParoliaMichigan Center for Translational Pathology, Ann Arbor, MI 48109, USA.
Yi-Mi WuMichigan Center for Translational Pathology, Ann Arbor, MI 48109, USA.
Noshad HosseiniDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.
Matthew SchipperDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, 48109, USA.
Anbarasu KumaraswamyRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Matthew McFarlaneRadiant Oncology, 2450 E River Rd, Tucson, AZ 85718.
Xuhong CaoMichigan Center for Translational Pathology, Ann Arbor, MI 48109, USA.
Phillip PalmbosDepartment of Internal Medicine, Division of Hematology/Oncology University of Michigan, Ann Arbor, MI, 48109, USA.
Megan CaramDepartment of Internal Medicine, Division of Hematology/Oncology University of Michigan, Ann Arbor, MI, 48109, USA.
David SmithDepartment of Internal Medicine, Division of Hematology/Oncology University of Michigan, Ann Arbor, MI, 48109, USA.
Sarah YentzDepartment of Internal Medicine, Division of Hematology/Oncology University of Michigan, Ann Arbor, MI, 48109, USA.
MI-OncoSeq Team, Stand-Up To Cancer Team
Maha H HussainRobert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
Thomas C WestbrookDepartment of Internal Medicine, Division of Hematology, Oncology and Cell Therapy, Rush University, Chicago, IL.
Daniel SprattDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio.
William C JacksonDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA.
Joshi J AlumkalMichigan Center for Translational Pathology, Ann Arbor, MI 48109, USA.
Zachery ReichertDepartment of Internal Medicine, Division of Hematology/Oncology University of Michigan, Ann Arbor, MI, 48109, USA.
Dan RobinsonMichigan Center for Translational Pathology, Ann Arbor, MI 48109, USA.
Arul M ChinnaiyanDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID 0000-0001-9282-3415
Robert DessDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA.
Marcin CieslikDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.

Funding

Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6M
NCI NIH HHS P50 CA186786
6 · The paper itself

Abstract

Rebernick et al. analyze a multi-institutional cohort of 1,331 prostate cancer samples and identify the genomic determinants of progression to lethal, castration-resistant disease. They define rare AR-regulated MYC fusions and haploinsufficient CDKN1B loss as drivers of poor outcome while highlighting AR alterations as predictors of improved prognosis. They develop CAPrisk, a multi-omic classifier that stratifies patient outcomes across androgen receptor pathway inhibitors, taxanes, PARP-inhibitors, and radium-223.

Indexed as

CDKN1Bchromosomal instabilityclinical genomicmCRPCmetastatic castration-resistant prostate cancerMYC gene fusionprognostic biomarkerProstate cancerwhole-genome duplication

Identifiers

PMID42528594
PMCPMC13411107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.